Serum and Urine Marker Screening for Fetal Aneuploidy

Aetna covers multiple serum marker testing (dimeric inhibin A, hCG with MSAFP, unconjugated estriol) for counseled pregnant women who desire risk information—offered to women <35 who want risk info and considered medically necessary for women ≥35 who decline invasive testing—and considers NIPT (cfDNA assays for trisomies 13, 18, 21 and X/Y when applicable; specified CPTs) medically necessary for screening in all pregnant women when selection criteria are met. NIPT is not necessary if a current pregnancy already had a negative multiple serum marker screen (±nuchal translucency), and tests such as DSCR4 methylation evaluation, Maternal Fetal Screen I T1, cfDNA for fetal RHD genotyping, microdeletion/microduplication screening, and rare autosomal trisomies are experimental/investigational and not covered.

"Potential reporting bias: outcomes inconsistent with the sgNIPS risk estimate may have been more frequently reported than those consistent with sgNIPS, which could artificially decrease calculated ..."